NCT03208179

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Sep 30, 2017
Primary completion: Aug 31, 2019
Completion date: Oct 31, 2019
First posted: —
Last posted: —
Enrollment: 4680
Arms / groups: 3 / —
Source: AACT · ingestion pipeline

Sponsors

University of LiverpoolLead sponsor
Kilimanjaro Christian Medical College, TanzaniaCollaborator
University of MassachusettsCollaborator
University of MalawiCollaborator
PATHCollaborator
University of LondonCollaborator
University of TorontoCollaborator
Centers for Disease Control and Prevention (CDC)Collaborator
Banook GroupCollaborator
Foundation for Innovative New Diagnostics (FIND)Collaborator
Intellectual Ventures LaboratoryCollaborator
Kenya Medical Research InstituteOverall official - principal investigator
Kenya Medical Research InstituteCollaborator
Kilimanjaro Christian Medical College, TanzaniaOverall official - principal investigator
Wellcome TrustCollaborator
Medical Research CouncilOverall official - principal investigator
Medical Research CouncilCollaborator
University of BergenCollaborator
University of CopenhagenCollaborator
University of MelbourneCollaborator
University of TampereCollaborator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.